Literature DB >> 19384951

An orthotopic endometrial cancer mouse model demonstrates a role for RUNX1 in distant metastasis.

Andreas Doll1, Marta Gonzalez, Miguel Abal, Marta Llaurado, Marina Rigau, Eva Colas, Marta Monge, Jordi Xercavins, Gabriel Capella, Berta Diaz, Antonio Gil-Moreno, Francesc Alameda, Jaume Reventos.   

Abstract

Endometrial carcinoma is the most common malignancy of the female genital tract in industrialized countries. Metastasis is the major cause of endometrial cancer deaths. Therefore, there is a vital need for clinically relevant in vivo models allowing the elucidation of the molecular and cellular mechanisms underlying metastatic behavior. In this study, we describe an innovative experimental orthotopic model of human endometrial carcinoma. Implantation in the bifurcation of the uterine horns resulted in tumors integrated into the myometrial compartment, which can be used and further exploited for the study of in vivo angiogenesis, myometrial invasion, and the metastatic capacity of endometrial cancer cells. This orthotopic model also represents a suitable tool to analyze how tumorigenesis and distant metastasis of endometrial cancer might be influenced by gene alteration, by modulating its expression in the original cancer cell line. One of the candidate genes implicated in endometrial cancer is the transcription factor RUNX1. The over-expression of RUNX1 in the endometrial cancer cell line HEC1A and the transplantation of these cells to the uterus of nude mice were associated specifically with distant metastasis in the lung. RUNX1 plays a role in the establishment of metastases in endometrial cancer. Translated to the clinics, these models would be equivalent to an advanced undifferentiated carcinoma with node affectation (stage IIIC) and distant metastasis (stage IVB). These patients would be candidates for adjuvant therapy, not efficient until today, and therefore, our models are actually suitable for the design and evaluation of experimental therapies. Copyright 2009 UICC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19384951     DOI: 10.1002/ijc.24330

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  24 in total

1.  Identification of RUNX1 as a Mediator of Aberrant Retinal Angiogenesis.

Authors:  Jonathan D Lam; Daniel J Oh; Lindsay L Wong; Dhanesh Amarnani; Cindy Park-Windhol; Angie V Sanchez; Jonathan Cardona-Velez; Declan McGuone; Anat O Stemmer-Rachamimov; Dean Eliott; Diane R Bielenberg; Tave van Zyl; Lishuang Shen; Xiaowu Gai; Patricia A D'Amore; Leo A Kim; Joseph F Arboleda-Velasquez
Journal:  Diabetes       Date:  2017-04-11       Impact factor: 9.461

2.  ERM/ETV5 and RUNX1/AML1 expression in endometrioid adenocarcinomas of endometrium and association with neoplastic progression.

Authors:  Vanessa Paiva Leite de Sousa; Claudia Bessa Pereira Chaves; Janina Ferreira Loureiro Huguenin; Fábio Carvalho de Barros Moreira; Bruno Souza Bianchi de Reis; Leila Chimelli; Anke Bergmann; Tatiana de Almeida Simão; Luis Felipe Ribeiro Pinto
Journal:  Cancer Biol Ther       Date:  2014-04-22       Impact factor: 4.742

Review 3.  The role of genetics in estrogen responses: a critical piece of an intricate puzzle.

Authors:  Emma H Wall; Sylvia C Hewitt; Laure K Case; Chin-Yo Lin; Kenneth S Korach; Cory Teuscher
Journal:  FASEB J       Date:  2014-09-11       Impact factor: 5.191

4.  miR-375 Regulates Invasion-Related Proteins Vimentin and L-Plastin.

Authors:  Lizandra Jimenez; Jihyeon Lim; Berta Burd; Thomas M Harris; Thomas J Ow; Nicole Kawachi; Thomas J Belbin; Ruth Angeletti; Michael B Prystowsky; Geoffrey Childs; Jeffrey E Segall
Journal:  Am J Pathol       Date:  2017-05-10       Impact factor: 4.307

5.  Generation and characterization of orthotopic murine models for endometrial cancer.

Authors:  Silvia Cabrera; Marta Llauradó; Josep Castellví; Yolanda Fernandez; Francesc Alameda; Eva Colás; Anna Ruiz; Andreas Doll; Simó Schwartz; Ramon Carreras; Jordi Xercavins; Miguel Abal; Antonio Gil-Moreno; Jaume Reventós
Journal:  Clin Exp Metastasis       Date:  2011-12-25       Impact factor: 5.150

6.  Runx1 is associated with breast cancer progression in MMTV-PyMT transgenic mice and its depletion in vitro inhibits migration and invasion.

Authors:  Gillian Browne; Hanna Taipaleenmäki; Nicole M Bishop; Sharath C Madasu; Leslie M Shaw; Andre J van Wijnen; Janet L Stein; Gary S Stein; Jane B Lian
Journal:  J Cell Physiol       Date:  2015-10       Impact factor: 6.384

7.  The RUNX1 transcription factor is expressed in serous epithelial ovarian carcinoma and contributes to cell proliferation, migration and invasion.

Authors:  Mamadou Keita; Magdalena Bachvarova; Chantale Morin; Marie Plante; Jean Gregoire; Marie-Claude Renaud; Alexandra Sebastianelli; Xuan Bich Trinh; Dimcho Bachvarov
Journal:  Cell Cycle       Date:  2013-02-26       Impact factor: 4.534

Review 8.  The RUNX family in breast cancer: relationships with estrogen signaling.

Authors:  N-O Chimge; B Frenkel
Journal:  Oncogene       Date:  2012-10-08       Impact factor: 9.867

9.  Deregulation of RAD21 and RUNX1 expression in endometrial cancer.

Authors:  Anna Supernat; Sylwia Lapińska-Szumczyk; Sambor Sawicki; Dariusz Wydra; Wojciech Biernat; Anna J Zaczek
Journal:  Oncol Lett       Date:  2012-07-09       Impact factor: 2.967

10.  Genetic control of estrogen-regulated transcriptional and cellular responses in mouse uterus.

Authors:  Emma H Wall; Sylvia C Hewitt; Liwen Liu; Roxana del Rio; Laure K Case; Chin-Yo Lin; Kenneth S Korach; Cory Teuscher
Journal:  FASEB J       Date:  2013-01-31       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.